







CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

	Email : c	customercare.hyderabad@srl.in	
PATIENT NAME : SHALINI CHINTAKUNT	LA	PATIENT ID : SI	HALF08018542
ACCESSION NO : 0042VL001904 AGE :	37 Years SEX : Female	ABHA NO :	
DRAWN : RECE	IVED : 14/12/2022 08:07	REPORTED : 15/12/2022	10:34
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :	
Test Report Status <u>Final</u>	Results	Biological Reference Inte	erval Units
MEDI WHEEL FULL BODY HEALTH CHECK	UP BELOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	12.8	12.0 - 15.0	g/dL
METHOD : CYANMETHEMOGLOBIN METHOD			-
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.55	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	7.80	4.0 - 10.0	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	278	150 - 410	thou/µL
METHOD : ELECTRICAL IMPEDANCE			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	39.4	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	86.0	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.0	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.4	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	12.6	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	18.9		
MEAN PLATELET VOLUME (MPV)	10.0	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	55	40 - 80	%
METHOD : ACV TECHNOLOGY			
LYMPHOCYTES	38	20 - 40	%
METHOD : ACV TECHNOLOGY			
MONOCYTES	3	2 - 10	%
METHOD : ACV TECHNOLOGY			
EOSINOPHILS	3	1 - 6	%
METHOD : ACV TECHNOLOGY			
BASOPHILS	1	0 - 2	%

METHOD : ACV TECHNOLOGY







F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI

NEW DELHI 110030

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)







Units

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA

DELHI INDIA Tel : 9111591115, Fax : 8800465156 CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in PATIENT NAME : SHALINI CHINTAKUNTLA PATIENT ID: SHALF08018542 ACCESSION NO : 0042VL001904 AGE: 37 Years SEX : Female ABHA NO : DRAWN : RECEIVED: 14/12/2022 08:07 **REPORTED** : 15/12/2022 10:34 **REFERRING DOCTOR :** CLIENT PATIENT ID: SELE **Test Report Status** Results Biological Reference Interval Final ABSOLUTE NEUTROPHIL COUNT 4.29 2.0 - 7.0 thou/µL METHOD : CALCULATED PARAMETER ABSOLUTE LYMPHOCYTE COUNT 2.96 1.0 - 3.0 thou/µL METHOD : CALCULATED PARAMETER 0.23 ABSOLUTE MONOCYTE COUNT 0.2 - 1.0 thou/µL METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT 0.23 0.02 - 0.50 thou/µL METHOD : CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT 0.08 0.02 - 0.10 thou/µL METHOD : CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.4 METHOD : CALCULATED MORPHOLOGY RBC NORMOCYTIC NORMOCHROMIC. METHOD : MICROSCOPIC EXAMINATION WBC WITHIN NORMAL LIMITS. METHOD : MICROSCOPIC EXAMINATION ADEQUATE ON SMEAR. PLATELETS METHOD : MICROSCOPIC EXAMINATION **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE** BLOOD E.S.R 14 0 - 20 mm at 1 hr METHOD : WESTERGREN METHOD **GLUCOSE FASTING, FLUORIDE PLASMA** FBS (FASTING BLOOD SUGAR) 74 - 99 96 mg/dL METHOD : SPECTROPHOTOMETRY HEXOKINASE **GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE** BLOOD HBA1C 5.0 Non-diabetic: < 5.7 % Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021) METHOD : ION- EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 96.8 METHOD : ION- EXCHANGE HPLC **GLUCOSE, POST-PRANDIAL, PLASMA**





mg/dL

< 116.0



NEW DELHI 110030

DELHI INDIA

8800465156

DRAWN:

CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110000



AGE : 37 Years

RECEIVED : 14/12/2022 08:07





SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

PATIENT NAME : SHALINI CHINTAKUNTLA

SHALF08018542 ABHA NO :

15/12/2022 10:34 **REPORTED** :

CLIENT PATIENT ID:

PATIENT ID:

REFERRING DOCTOR : SELF

ACCESSION NO : **0042VL001904**

Test Report Status	<u>Final</u>	Results	Biological Reference Interv	al Units
PPBS(POST PRANDIAL B METHOD : SPECTROPHOTOME	TRY HEXOKINASE	110	70 - 139	mg/dL
LIPID PROFILE, SERU CHOLESTEROL, TOTAL		141	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : SPECTROPHOTOME TRIGLYCERIDES		ESTERASE PEROXIDASE 55	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : SPECTROPHOTOME		41	< 40 Low >/=60 High	mg/dL
METHOD : SPECTROPHOTOME	IRY,POLYANIONIC DETERGEN	т/снод 92	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL	-	100	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
CHOL/HDL RATIO		3.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO		2.2	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIP		11	= 30.0</td <td>mg/dL</td>	mg/dL
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOME	TRY, JENDRASSIK & GROFF	0.54	0.2 - 1.0	mg/dL
BILIRUBIN, DIRECT METHOD : SPECTROPHOTOME	TRY, JENDRASSIK & GROFF	0.17	0.0 - 0.2	mg/dL

SEX : Female





DELHI INDIA

8800465156

CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030







SHALF08018542

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

PATIENT ID:

CLIENT PATIENT ID:

PATIENT NAME : SHALINI CHINTAKUNTLA

ACCESSION NO :	0042VL001904	AGE: 37 Years	SEX : Female	ABHA NO :	
DRAWN :		RECEIVED : 14/1	2/2022 08:07	REPORTED :	15/12/2022 10:34

REFERRING DOCTOR : SELF

BILIRUBIN, INDIRECT 0.37 0.1 - 1.0 mg/dL BILIRUBIN, INDIRECT 0.37 0.1 - 1.0 mg/dL METHOD::::::::::::::::::::::::::::::::::::	Test Report Status	<u>Final</u>	Results	Biological Reference I	nterval Units
METHOD: SPECTROPHOTOMETRY, CALCULATED 7.0 6.4 - 8.2 g/dL METHOD: SPECTROPHOTOMETRY, MODIFIED BUINET 3.7 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRY, BCP - DVE BINDING 3.3 2.0 - 4.1 g/dL METHOD: SPECTROPHOTOMETRY, CALCULATED 3.3 2.0 - 4.1 g/dL METHOD: SPECTROPHOTOMETRY, CALCULATED 3.3 2.0 - 4.1 g/dL METHOD: SPECTROPHOTOMETRY, CALCULATED 3.3 2.0 - 4.1 RATIO METHOD: SPECTROPHOTOMETRY, CALCULATED 3.3 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, CALCULATED 3.3 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, UW WITH PRITEDXAL -S-PHOSPHATE V/L 1.1 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, UW WITH PRITEDXAL -S-PHOSPHATE V/L 1.1 1.0 - 2.1 1.0 - 2.1 ALANINE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 V/L 1.0 - 2.1					
TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BURGT 3.7 3.4 - 5.0 g/dL METHOD : SPECTROPHOTOMETRY, DEP - DYE BINDING 3.3 2.0 - 4.1 g/dL METHOD : SPECTROPHOTOMETRY, CALCULATED 1.0 - 2.1 RATIO ALBUMIN/GLOBULIN RATIO 1.1 1.0 - 2.1 RATIO METHOD : SPECTROPHOTOMETRY, CALCULATED 1 1.0 - 2.1 RATIO ALBUMIN/GLOBULIN RATIO 1.1 1.0 - 2.1 RATIO METHOD : SPECTROPHOTOMETRY, VU WITH PRIDOXAL -S-PHOSPHATE 0 V/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0			0.37	0.1 - 1.0	mg/dL
METHOD : SPECTROPHOTOMETRY, MODIFIED BURNET 3.7 3.4 - 5.0 g/dL METHOD : SPECTROPHOTOMETRY, BCP - DYE BINDING 3.3 2.0 - 4.1 g/dL BLOUND : SPECTROPHOTOMETRY, CALCULATED 1.1 0.2.0 - 4.1 g/dL METHOD : SPECTROPHOTOMETRY, CALCULATED 1.1 1.0 - 2.1 RETHOD : SPECTROPHOTOMETRY, CALCULATED ASPARTATE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 U/L METHOD : SPECTROPHOTOMETRY, UW ITH PYRIDOXAL - 5-PHOSPHATE 434.0 U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0		1ETRY,CALCULATED			
ALBUMIN 3.7 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRY, BCP - DRE BINDING 3.3 2.0 - 4.1 g/dL GLOBULIN SPECTROPHOTOMETRY, CALCULATED 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, CALCULATED 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, CALCULATED 1.1 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, CALCULATED 1.1 1.0 - 2.1 RATIO METHOD: SPECTROPHOTOMETRY, UW WITH PRIDOXAL-5: PHOSPHATE 1.1 1.1 1.1 ALANINE AMINOTRANSFERASE (ALT/SGOT) 28 < 34.0			7.0	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY, BCP - DYE BINDING		1ETRY, MODIFIED BIURET			
GLOBULIN 3.3 2.0 - 4.1 g/dL METHOD::SPECTROPHOTOMETRY, CALCULATED NATIO NATIO METHOD::SPECTROPHOTOMETRY, CALCULATED 10.0 - 2.1 RATIO ASPARTATE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 U/L METHOD::SPECTROPHOTOMETRY, CALCULATED 3 30.0 - 200 U/L METHOD::SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -S-PHOSPHATE 30.0 - 120 U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0			3.7	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY,CALCULATED ALBUMIN/GLOBULIN RATIO 1.1 1.0 - 2.1 RATIO METHOD : SPECTROPHOTOMETRY,CALCULATED ASPARTATE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 U/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL - 5-PHOSPHATE ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0 U/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL - 5-PHOSPHATE ALKALINE PMOSPHATASE 33 30 - 120 U/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL - 5-PHOSPHATE ALKALINE PMOSPHATASE 33 30 - 120 U/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL - 5-PHOSPHATE ALKALINE PMOSPHATASE 33 30 - 120 U/L METHOD : SPECTROPHOTOMETRY, D-NPP (AMP BUFFER) GAMMA GLUTAMYL TRANSFERASE (GGT) 33 5 - 55 U/L METHOD : SPECTROPHOTOMETRY, G-UITAMYL-CARBOYL-NITRONILIDE LACTATE DEHYDROGENASE 163 100 - 190 U/L METHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATE BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM CREATININE 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE UV CREATININE SERUM CREATININE SERUM CREATININE SERUM UNIC ACID 8.75 5.00 - 15.00 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO BUN/CREAT RATIO BU		1etry, BCP - Dye Binding			
ALBUMIN/GLOBULIN RATIO1.11.0 - 2.1RATIOMETHOD : SPECTROPHOTOMETRY, CALCULATED15 - 37U/LASPARTATE AMINOTRANSFERASE (AST/SQT)115 - 37U/LMETHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -S-PHOSPHATE34.0U/LALANINE AMINOTRANSFERASE (ALT/SGP)28<34.0			3.3	2.0 - 4.1	g/dL
METHOD : SPECTROPHOTOMETRY, CALCULATED ASPARTATE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 U/L METHOD : SPECTROPHOTOMETRY, UW UTH I PRIDOXAL -S-PHOSPHATE 28 < 34.0		•			
ASPARTATE AMINOTRANSFERASE (AST/SGOT) 15 15 - 37 V/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHOSPHATE 3 34.0 V/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHOSPHATE 3 30 - 120 V/L METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHOSPHATE 3 30 - 120 V/L METHOD : SPECTROPHOTOMETRY, PNPP (AMP BUFFER) 33 5 - 55 V/L GAMMA GLUTAMYL TRANSFERASE (GGT) 33 5 - 55 V/L METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILLOE Into - 190 V/L METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILLOE Into - 190 V/L BLOOD UREA NITROGEN (BUN), SERUM Into - 190 V/L BLOOD UREA NITROGEN (BUN), SERUM Into - 190 Mg/L METHOD : SPECTROPHOTOMETRY, UREASE UV Into - 190 Mg/L CREATININE, SERUM 0.80 0.60 - 1.10 Mg/L METHOD : SPECTROPHOTOMETRY, UREASE UV Into - 190 Mg/L CREATININE 0.80 0.60 - 1.10 Mg/L METHOD : SPECTROPHOTOMETRY, UREASE UV Into - 190 Mg/L URIC ACID, SERUM Into - 190 Mg/L <td>ALBUMIN/GLOBULIN R</td> <td>ΑΠΟ</td> <td>1.1</td> <td>1.0 - 2.1</td> <td>RATIO</td>	ALBUMIN/GLOBULIN R	ΑΠΟ	1.1	1.0 - 2.1	RATIO
METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL - S-PHOSPHATE V/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0	METHOD : SPECTROPHOTOM	IETRY,CALCULATED			
ALANINE AMINOTRANSFERASE (ALT/SGPT) 28 < 34.0	ASPARTATE AMINOTRA	ANSFERASE (AST/SGOT)	15	15 - 37	U/L
METHOD : SPECTROPHOTOMETRY, UV WITH PIRIDOXAL -S-PHOSPHATE ALKALINE PHOSPHATASE 33 30 - 120 U/L METHOD : SPECTROPHOTOMETRY, P-NPP (AMP BUFFER) GAMMA GLUTAMYL TRANSFERASE (GGT) 33 5 - 55 U/L METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE LACTATE DEHYDROGENASE 163 100 - 190 U/L METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM CREATININE, SERUM CREATININE, SERUM CREATININE, SERUM CREATININE 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY, CALCULATED URIC ACID, SERUM URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM METHOD : SPECTROPHOTOMETRY, URICASE	METHOD : SPECTROPHOTOM	IETRY, UV WITH PYRIDOXAL -5-PHOS	PHATE		
ALKALINE PHOSPHATASE 33 30 - 120 U/L METHOD : SPECTROPHOTOMETRY, P-NPP (AMP BUFFER) 33 5 - 55 U/L GAMMA GLUTAMYL TRANSFERASE (GGT) 33 5 - 55 U/L METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE 100 - 190 U/L LACTATE DEHYDROGENASE 163 100 - 190 U/L METHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE > PYRUVATE SECOD UREA NITROGEN (BUN), SERUM U/L BLOOD UREA NITROGEN (BUN), SERUM 6 - 20 mg/dL CREATININE, SERUM 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S SECOPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S SECOPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO 8.75 5.00 - 15.00 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S SECOPHOTOMETRY, CALCULATED SECOPHOTOMETRY, CALCULATED URIC ACID 8.75 5.00 - 15.00 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE SECOPHOTOMETRY, URICASE SECOPHOTOMETRY, URICASE URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE SECOPHOTOMETRY, URICASE <	ALANINE AMINOTRANS	SFERASE (ALT/SGPT)	28	< 34.0	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)335 - 55U/LGAMMA GLUTAMYL TRANSFERASE (GGT)335 - 55U/LMETHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE163100 - 190U/LLACTATE DEHYDROGENASE163100 - 190U/LMETHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATESSSBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLCREATININE, SERUM0.800.60 - 1.10mg/dLCREATININE, SERUM0.800.60 - 1.10mg/dLMETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'SSSSSUN/CREAT RATIO8.755.00 - 15.00SMETHOD : SPECTROPHOTOMETRY, CALCULATEDURIC ACID, SERUMURIC ACID, SERUMSURIC ACID, SERUM3.62.6 - 6.0mg/dLURIC ACID3.62.6 - 6.0mg/dLMETHOD : SPECTROPHOTOMETRY, URICASETOTAL PROTEIN, SERUMSMETHOD : SPECTROPHOTOMETRY, URICASETOTAL PROTEIN, SERUMSMETHOD : SPECTROPHOTOMETRY, URICASESSSMETHOD : SPECTROPHOTOMETRY, URICASESSSURIC ACID3.62.6 - 6.0Mg/dLMETHOD : SPECTROPHOTOMETRY, URICASESSSMETHOD : SPECTROPHOTOMETRY, URICASESSSMETHOD : SPECTROPHOTOMETRY, URICASESSSMETHOD : SPECTROPHOT	METHOD : SPECTROPHOTOM	IETRY, UV WITH PYRIDOXAL -5-PHOS	PHATE		
GAMMA GLUTAMYL TRANSFERASE (GGT)335 - 55U/LMETHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE100 - 190U/LLACTATE DEHYDROGENASE163100 - 190U/LMETHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATEHETHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATEHETHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATEBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLMETHOD : SPECTROPHOTOMETRY, UREASE UV76 - 20mg/dLCREATININE, SERUMCREATININE, SERUM0.800.60 - 1.10mg/dLMETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'SHETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'SHETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'SVIRIC ACID, SERUMBUN/CREAT RATIO8.755.00 - 15.00METHOD : SPECTROPHOTOMETRY, CALCULATEDURIC ACID, SERUMURIC ACID, SERUMURIC ACID, SERUMTOTAL PROTEIN, SERUMTOTAL PROTEIN, SERUMTOTAL PROTEIN, SERUMTOTAL PROTEIN, SERUMTOTAL PROTEIN, SERUMMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	ALKALINE PHOSPHATA	SE	33	30 - 120	U/L
METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDELACTATE DEHYDROGENASE163100 - 190U/LMETHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATEBLOOD UREA NITROGEN (BUN), SERUM86 - 20mg/dLBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLBLOOD UREA NITROGEN (BUN), SERUM76 - 20mg/dLCREATININE, SERUM0.800.60 - 1.10mg/dLCREATININE , SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S*mg/dL* BUN/CREAT RATIO METHOD : SPECTROPHOTOMETRY, CALCULATED8.755.00 - 15.00METHOD : SPECTROPHOTOMETRY, CALCULATED***URIC ACID, SERUM3.62.6 - 6.0mg/dLURIC ACID METHOD : SPECTROPHOTOMETRY, URICASE3.62.6 - 6.0mg/dLTOTAL PROTEIN, SERUM7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURET%%%	METHOD : SPECTROPHOTOM	IETRY, P-NPP (AMP BUFFER)			
LACTATE DEHYDROGENASE 163 100 - 190 U/L METHOD : SPECTROPHOTOMETRY, MODIFIED EXYMATIC LACTATE - PYRUVATE BLOOD UREA NITROGEN (BUN), SERUM 7 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE UV 7 6 - 20 mg/dL CREATININE, SERUM 7 0.60 - 1.10 mg/dL CREATININE 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY, CALCULATED 3.6 2.6 - 6.0 mg/dL VIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE Mg/dL URIC ACID 3.6 2.6 - 6.0 mg/dL <t< td=""><td>GAMMA GLUTAMYL TRA</td><td>ANSFERASE (GGT)</td><td>33</td><td>5 - 55</td><td>U/L</td></t<>	GAMMA GLUTAMYL TRA	ANSFERASE (GGT)	33	5 - 55	U/L
METHOD : SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTATE - PYRUVATE BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM METHOD : SPECTROPHOTOMETRY, UREASE UV CREATININE, SERUM CREATININE, SERUM CREATININE 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE' * BUN/CREAT RATIO BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY, CALCULATED URIC ACID, SERUM URIC ACID, SERUM URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	METHOD : SPECTROPHOTOM	IETRY, G-GLUTAMYL-CARBOXY-NITRO	NILIDE		
BLOOD UREA NITROGEN (BUN), SERUMBLOOD UREA NITROGEN76 - 20mg/dLMETHOD : SPECTROPHOTOMETRY, UREASE UVCREATININE, SERUMCREATININE0.800.60 - 1.10mg/dLMETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'Smg/dL* BUN/CREAT RATIOBUN/CREAT RATIO8.755.00 - 15.00METHOD : SPECTROPHOTOMETRY, CALCULATEDURIC ACID, SERUMURIC ACID, SERUM3.62.6 - 6.0mg/dLMETHOD : SPECTROPHOTOMETRY, URICASE3.62.6 - 6.0mg/dLTOTAL PROTEIN, SERUMTOTAL PROTEIN7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURETMg/dLMg/dL	LACTATE DEHYDROGE	NASE	163	100 - 190	U/L
BLOOD UREA NITROGEN 7 6 - 20 mg/dL METHOD : SPECTROPHOTOMETRY, UREASE UV CREATININE, SERUM Mg/dL CREATININE, SERUM 0.80 0.60 - 1.10 mg/dL CREATININE 0.80 0.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * * * BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY, CALCULATED * * URIC ACID, SERUM 3.6 2.6 - 6.0 mg/dL URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE * * TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL	METHOD : SPECTROPHOTOM	IETRY, MODIFIED ENZYMATIC LACTATI	E - PYRUVATE		
METHOD : SPECTROPHOTOMETRY, UREASE UV CREATININE, SERUM CREATININE SERUM CREATININE ON O.60 - 1.10 mg/dL METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO BUN/CREAT RATIO BUN/CREAT RATIO METHOD : SPECTROPHOTOMETRY, CALCULATED VIRIC ACID, SERUM URIC ACID SERUM URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL	BLOOD UREA NITRO	GEN (BUN), SERUM			
CREATININE, SERUMCREATININE0.800.60 - 1.10mg/dLMETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S*** BUN/CREAT RATIO8.755.00 - 15.00*METHOD : SPECTROPHOTOMETRY, CALCULATED***URIC ACID, SERUM3.62.6 - 6.0mg/dLURIC ACID3.62.6 - 6.0mg/dLMETHOD : SPECTROPHOTOMETRY, URICASE***TOTAL PROTEIN, SERUM7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURET***	BLOOD UREA NITROGE	EN	7	6 - 20	mg/dL
CREATININE0.800.60 - 1.10mg/dLMETHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S***	METHOD : SPECTROPHOTON	1ETRY, UREASE UV			
METHOD : SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC JAFFE'S * BUN/CREAT RATIO BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY,CALCULATED URIC ACID, SERUM URIC ACID, SERUM URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	CREATININE, SERUM	1			
* BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY,CALCULATED	CREATININE		0.80	0.60 - 1.10	mg/dL
BUN/CREAT RATIO 8.75 5.00 - 15.00 METHOD : SPECTROPHOTOMETRY,CALCULATED URIC ACID, SERUM URIC ACID SERUM METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN MODIFIED BIURET TOTAL PROTEIN MODIFIED BIURET	METHOD : SPECTROPHOTON	1ETRY, ALKALINE PICRATE KINETIC JA	FFE'S		
METHOD : SPECTROPHOTOMETRY,CALCULATED URIC ACID, SERUM URIC ACID 3.6 2.6 - 6.0 mg/dL METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	* BUN/CREAT RATIO	ס			
URIC ACID, SERUMURIC ACID3.62.6 - 6.0mg/dLMETHOD : SPECTROPHOTOMETRY, URICASETOTAL PROTEIN, SERUMTOTAL PROTEIN, SERUMg/dLTOTAL PROTEIN7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURETTOTAL PROTEINg/dL	BUN/CREAT RATIO		8.75	5.00 - 15.00	
URIC ACID3.62.6 - 6.0mg/dLMETHOD : SPECTROPHOTOMETRY, URICASETOTAL PROTEIN, SERUMJobJobJobJobTOTAL PROTEIN7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURETJobJobJobJob	METHOD : SPECTROPHOTOM	IETRY,CALCULATED			
METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	URIC ACID, SERUM				
METHOD : SPECTROPHOTOMETRY, URICASE TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET	-		3.6	2.6 - 6.0	mg/dL
TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET 7.0 6.4 - 8.2 g/dL		1ETRY, URICASE	-		
TOTAL PROTEIN7.06.4 - 8.2g/dLMETHOD : SPECTROPHOTOMETRY, MODIFIED BIURET		•			
METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET			7.0	6.4 - 8.2	a/dl
		IETRY, MODIFIED BIURET		011 012	9, 42
	ALBUMIN, SERUM	,			













SHALF08018542

CLIENT CODE: C000138369 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

PATIENT ID:

CLIENT PATIENT ID:

15/12/2022 10:34

PATIENT NAME : SHALINI CHINTAKUNTLA ACCESSION NO : 0042VL001904 AGE : 37 Years SEX : Female ABHA NO : DRAWN : RECEIVED : 14/12/2022 08:07 REPORTED :

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
ALBUMIN	3.7	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY, BCP - DYE BINDING			
* GLOBULIN			
GLOBULIN	3.3	2.0 - 4.1	g/dL
METHOD : SPECTROPHOTOMETRY,CALCULATED			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	145	136 - 145	mmol/L
METHOD : INTEGRATED MULTISENSOR TECHNOLOGY-INDIRECT			
POTASSIUM, SERUM	5.02	3.50 - 5.10	mmol/L
METHOD : INTEGRATED MULTISENSOR TECHNOLOGY-INDIRECT			
CHLORIDE, SERUM	100	98 - 107	mmol/L
METHOD : INTEGRATED MULTISENSOR TECHNOLOGY-INDIRECT			
Interpretation(s)			
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
METHOD : MANUAL			
APPEARANCE	CLEAR		
METHOD : MANUAL			
CHEMICAL EXAMINATION, URINE			
PH	7.0	4.7 - 7.5	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
SPECIFIC GRAVITY	1.005	1.003 - 1.035	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
UROBILINOGEN	NORMAL	NORMAL	
METHOD : REFLECTANCE SPECTROPHOTOMETRY			
NITRITE	NOT DETECTED	NOT DETECTED	







F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030

DELHI INDIA

8800465156

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)







SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

PATIENT NAME : SHALINI CHINTAKUNTLA PATIENT ID: SHALF08018542 ACCESSION NO : **0042VL001904** AGE: 37 Years SEX : Female ABHA NO : RECEIVED : 14/12/2022 08:07 15/12/2022 10:34 DRAWN: **REPORTED** : REFERRING DOCTOR : SELF CLIENT PATIENT ID : **Test Report Status** Results **Biological Reference Interval** Units **Final** METHOD : REFLECTANCE SPECTROPHOTOMETRY LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED **MICROSCOPIC EXAMINATION, URINE RED BLOOD CELLS** NOT DETECTED NOT DETECTED /HPF

METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	

Comments

NOTE : URINE MICROSCOPIC EXAMINATION IS CARRIED OUT ON CENTRIFUGED URINE SEDIMENT.

Interpretation(s)

THYROID PANEL, SERUM			
ТЗ	115.70	80.00 - 200.00	ng/dL
METHOD : ECLIA			
T4	9.01	5.10 - 14.10	µg/dL
METHOD : ECLIA			
TSH (ULTRASENSITIVE)	0.830	Non Pregnant Women 0.27 - 4.20	µIU/mL
		Pregnant Women	
		1st Trimester: 0.33 - 4.59	
		2nd Trimester: 0.35 - 4.10	
		3rd Trimester: 0.21 - 3.15	













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 14/12/2022 08:07	REPORTED : 15/12/2022 10:34
ACCESSION NO : 0042VL0019	AGE : 37 Years SEX : Female	ABHA NO :
PATIENT NAME : SHALINI C	HINTAKUNTLA	PATIENT ID : SHALF08018542

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
			-		Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

* LETTER

ADDITIONAL COMMUNICATION

MICROSCOPIC EXAMINATION, STOOL

REMARK

Interpretation(s)

SAMPLE NOT RECEIVED

SAMPLE NOT RECEIVED













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

	Email : cu	istomercare.hyderabad@srl.in
PATIENT NAME : SHALINI CHINT	AKUNTLA	PATIENT ID : SHALF08018542
ACCESSION NO : 0042VL001904	AGE : 37 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 14/12/2022 08:07	REPORTED : 15/12/2022 10:34
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
ABO GROUP & RH TYPE, EDTA WH	IOLE BLOOD	
ABO GROUP	TYPE A	
METHOD : TUBE AGGLUTINATION		
RH TYPE	POSITIVE	
METHOD : TUBE AGGLUTINATION		
* XRAY-CHEST		
»»	BOTH THE LUNG FIELDS	ARE CLEAR
»»	BOTH THE COSTOPHREN	IC AND CARIOPHRENIC ANGELS ARE CLEAR
»»	BOTH THE HILA ARE NOF	RMAL
»»	CARDIAC AND AORTIC S	HADOWS APPEAR NORMAL
»»	BOTH THE DOMES OF TH	E DIAPHRAM ARE NORMAL
»»	VISUALIZED BONY THOR	RAX IS NORMAL
IMPRESSION	NO ABNORMALITY DETEC	CTED
TMT OR ECHO		
TMT OR ECHO	PATIENT NOT WANT TO D	DO 2D ECHO TEST
* ECG		
ECG	WITHIN NORMAL LIMITS	
* MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	NOT SIGNIFICANT	
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT	
RELEVANT FAMILY HISTORY	NOT SIGNIFICANT	
OCCUPATIONAL HISTORY	NOT SIGNIFICANT	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
* ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.67	mts
WEIGHT IN KGS.	73	Kgs
ВМІ	26	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
* GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
	NORMAL	

NORMAL



PHYSICAL ATTITUDE











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

Email : customercare.hyderabad@srl.in PATIENT NAME : SHALINI CHINTAKUNTLA PATIENT ID: SHALF08018542 ACCESSION NO : 0042VL001904 AGE: 37 Years SEX : Female ABHA NO : DRAWN: RECEIVED: 14/12/2022 08:07 **REPORTED** : 15/12/2022 10:34 **REFERRING DOCTOR :** CLIENT PATIENT ID: SELF **Test Report Status** Results **Biological Reference Interval** Units Final GENERAL APPEARANCE / NUTRITIONAL STATUS HEALTHY **BUILT / SKELETAL FRAMEWORK** AVERAGE FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER THYROID GLAND NOT ENLARGED CAROTID PULSATION NORMAL BREAST (FOR FEMALES) NORMAL **TEMPERATURE** NORMAL PULSE 70/REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT RESPIRATORY RATE NORMAL * CARDIOVASCULAR SYSTEM 90/60 MM HG BP mm/Hg (SITTING) PERICARDIUM NORMAL APEX BEAT NORMAL HEART SOUNDS NORMAL MURMURS ABSENT *** RESPIRATORY SYSTEM** SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL BREATH SOUNDS INTENSITY NORMAL BREATH SOUNDS QUALITY VESICULAR (NORMAL) ADDED SOUNDS ABSENT *** PER ABDOMEN** APPEARANCE NORMAL VENOUS PROMINENCE ABSENT LIVER NOT PALPABLE

NOT PALPABLE

ABSENT

*** CENTRAL NERVOUS SYSTEM**



SPLEEN

HERNIA





DELHI INDIA

8800465156







CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

CLIENT PATIENT ID:

PATIENT NAME : SHALINI CHINTAKUNTLA

PATIENT ID : SHALF08018542

ACCESSION NO :	0042VL001904	AGE: 37 Years	SEX : Female	ABHA NO :	
DRAWN :		RECEIVED : 14/1	2/2022 08:07	REPORTED :	15/12/2022 10:34

REFERRING DOCTOR : SELF

Test Report Status <u>Final</u>		Results	Biological Reference Interval Uni	ts
HIGHER FUNCTIONS		NORMAL		
CRANIAL NERVES		NORMAL		
CEREBELLAR FUNCTIONS		NORMAL		
SENSORY SYSTEM		NORMAL		
MOTOR SYSTEM		NORMAL		
REFLEXES		NORMAL		
* MUSCULOSKELETAL SYSTEM	l			
SPINE		NORMAL		
JOINTS		NORMAL		
* BASIC EYE EXAMINATION				
CONJUNCTIVA		NORMAL		
EYELIDS		NORMAL		
EYE MOVEMENTS		NORMAL		
CORNEA		NORMAL		
DISTANT VISION RIGHT EYE WIT	HOUT GLASSES	6/12		
DISTANT VISION LEFT EYE WITH	OUT GLASSES	6/12		
NEAR VISION RIGHT EYE WITHO	UT GLASSES	WITHIN NORMAL LI	IMIT	
NEAR VISION LEFT EYE WITHOUT	Γ GLASSES	WITHIN NORMAL LI	IMIT	
COLOUR VISION		NORMAL		
* BASIC ENT EXAMINATION				
EXTERNAL EAR CANAL		NORMAL		
TYMPANIC MEMBRANE		NORMAL		
NOSE		NO ABNORMALITY D	DETECTED	
SINUSES		NORMAL		
THROAT		NO ABNORMALITY D	DETECTED	
TONSILS		NOT ENLARGED		
* BASIC DENTAL EXAMINATION	N			
TEETH		NORMAL		
GUMS		HEALTHY		
* SUMMARY				
RELEVANT HISTORY		NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FIN	DINGS	NOT SIGNIFICANT		
RELEVANT LAB INVESTIGATIONS		USG -REVEALS BU	LKY UTERUS WITH MULTIPLE FIBROIDS.	













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

PATIENT NAME : SHALINI CHINTAKUNTLA PATIENT ID: SHALF08018542 ACCESSION NO : 0042VL001904 AGE: 37 Years SEX : Female ABHA NO : DRAWN : RECEIVED: 14/12/2022 08:07 **REPORTED** : 15/12/2022 10:34 REFERRING DOCTOR : SELF CLIENT PATIENT ID: Test Report Status Results Biological Reference Interval Units Final

RELEVANT NON PATHOLOGY DIAGNOSTICS **REMARKS / RECOMMENDATIONS**

OVERWEIGHT.

AVOID OILY AND JUNK FOODS.PHYSICAL EXCERCISES ARE SUGGEST. ADVICE TO FOLLOW UP WITH GYNAECOLOGIST FOR BULKY UTERUS WITH MULTIPLE FIBROIDS.

*** FITNESS STATUS**

FITNESS STATUS

FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE .

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition. GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical,

stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic



Scan to View Details











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

REFERRING DOCTOR : SELF	CLIENT PATIENT ID:
DRAWN : RECEIVED : 14/12/2022	2 08:07 REPORTED : 15/12/2022 10:34
ACCESSION NO : 0042VL001904 AGE : 37 Years SEX :	· Female ABHA NO :
PATIENT NAME : SHALINI CHINTAKUNTLA	PATIENT ID : SHALF08018542

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes. 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to : I.Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin. III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, (indirect) bilirubin in Viral hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis. ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)

Muscle problems, such as breakdown of muscle fibers
Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy



Scan to View Details

Page 12 Of 14 Scan to View Report









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

Test Report Status Fin	al	Results Bi	iological Re	ference Ir	nterval Units
REFERRING DOCTOR : SELF			CLIENT F	PATIENT ID:	
DRAWN :	RECEIVED : 14/1	2/2022 08:07 RE	EPORTED :	15/12/2022	2 10:34
ACCESSION NO : 0042VL00	01904 AGE : 37 Years	SEX : Female AE	3HA NO :		
PATIENT NAME : SHALIN	I CHINTAKUNTLA		ΡΑΤΙ	ENT ID:	SHALF08018542

URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum ... Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''s disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ÁLBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-

Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history; as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

 Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:
 Fit (As per requested panel of tests) – SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for. • Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been

detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician's consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job. • Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal

the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.

• Unfit (As per requested panel of tests) - An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956 Email : customercare.hyderabad@srl.in

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 14/12/2022 08:07	REPORTED : 15/12/2022 10:34
ACCESSION NO : 0042VL001	904 AGE : 37 Years SEX : Female	ABHA NO :
PATIENT NAME : SHALINI	CHINTAKUNTLA	PATIENT ID : SHALF08018542

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

* ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN BULKY UTERS WITH MULTIPLE FIBROIDS

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

Dr M. Prasanthi Consultant Microbiologist

Dr. Ravi Teja J Consultant Pathologist

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
 Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

- Test results cannot be used for Medico legal purposes.
 In case of queries please call customer care
- (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



